Persson H, Nordén G, Karlberg I, Friman S
Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden.
Transpl Int. 1994 May;7(3):172-6. doi: 10.1007/BF00327083.
Cyclosporin nephrotoxicity is a well-known complication in organ transplantation. In successful liver transplantation, a moderate degree of renal impairment is accepted. Whether this impairment is continuously progressive, stabilizes with time, or is reversible is not known. We have prospectively evaluated the glomerular filtration rate (GFR) using 51CrEDTA plasma clearance in 29 liver transplant patients (11 males and 18 females) with a mean age of 49 years (range 22-62 years). The 51CrEDTA plasma clearance measurements were performed preoperatively and at 3, 6, 12, 24, and 36 months after the liver transplantation. All but six patients were given sequential, quadruple drug therapy with antithymocyte globulin, azathioprine, steroids, and cyclosporin. Intravenous cyclosporin was avoided and oral cyclosporin started when renal function was stable. Cyclosporin was started in a dose of 8 mg/kg body weight, aiming at whole blood through levels (specific monoclonal technique) of 200 micrograms/l in the postoperative period; thereafter, the dosage was rapidly tapered down, aiming at whole blood trough levels of less than 100 micrograms/l at 3 months (1.5-2 mg/kg body weight). From a mean preoperative GFR of 89 +/- 3 ml/min per 1.73 m2, all patients declined in renal function after transplantation to a mean of 64 +/- 4 ml/min per 1.73 m2 3 months after transplantation, and starting in the 3rd month the renal function was stable at about 70% of the preoperative value. No correlations were found between cyclosporin peak level or accumulated cyclosporin dose and renal impairment. We conclude that liver transplantation with cyclosporin immunosuppression will induce renal impairment even if cyclosporin blood levels are carefully monitored and kept low.(ABSTRACT TRUNCATED AT 250 WORDS)
环孢素肾毒性是器官移植中一种众所周知的并发症。在成功的肝移植中,一定程度的肾功能损害是可接受的。但这种损害是持续进展、随时间稳定还是可逆尚不清楚。我们前瞻性地使用51CrEDTA血浆清除率评估了29例肝移植患者(11例男性和18例女性)的肾小球滤过率(GFR),这些患者的平均年龄为49岁(范围22 - 62岁)。在肝移植术前以及术后3、6、12、24和36个月进行了51CrEDTA血浆清除率测量。除6例患者外,所有患者均接受了抗胸腺细胞球蛋白、硫唑嘌呤、类固醇和环孢素的序贯四联药物治疗。避免静脉使用环孢素,在肾功能稳定时开始口服环孢素。环孢素起始剂量为8mg/kg体重,术后目标全血谷浓度(特定单克隆技术)为200μg/l;此后,剂量迅速递减,目标是3个月时全血谷浓度低于100μg/l(1.5 - 2mg/kg体重)。从术前平均GFR每1.73m2 89±3ml/min开始,所有患者移植后肾功能均下降,移植后3个月平均降至每1.73m2 64±4ml/min,从第3个月开始肾功能稳定在术前值的约70%。未发现环孢素峰值水平或累积环孢素剂量与肾功能损害之间存在相关性。我们得出结论,即使仔细监测并保持环孢素血药浓度较低,采用环孢素免疫抑制的肝移植仍会导致肾功能损害。(摘要截短于250字)